Resveratrol and diabetes: A critical review of clinical studies

Biomedicine and Pharmacotherapy

Volumn 95, Issue , 2017, Pages 230-234

  Öztürk, Ebru ^a   Arslan, Ayşe Kübra Karaboğa ^a   Yerer, Mükerrem Betül ^a   Bishayee, Anupam ^b  

^a ERCIYES UNIVERSITY   (Turkey)

^b Larkin University   (United States)

Author keywords

Clinical trials; Diabetes mellitus; Hyperglycemia; Insulin; Resveratrol; Therapy; Trans resveratrol

Indexed keywords

INSULIN; RESVERATROL; ANTIDIABETIC AGENT; STILBENE DERIVATIVE;

BIOCHEMISTRY; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; DRUG EFFECT; HUMAN; INSULIN SENSITIVITY; PRIORITY JOURNAL; REVIEW; ANIMAL; BLOOD; CHEMISTRY; GLUCOSE BLOOD LEVEL; METABOLISM; PROCEDURES;

ANIMALS; BLOOD GLUCOSE; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS; HUMANS; HYPOGLYCEMIC AGENTS; STILBENES;

EID: 85027979137     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2017.08.070     Document Type: Review

References (66)

1. Bhatt, J.K., Thomas, S., Nanjan, M.J., Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus. Nutr. Res. 32:7 (2012), 537–541.
2. Krithika, V., Naik, R., Functional properties of grape (Vitis vinifera) seed extract and possible extraction techniques – a review. Agric. Res. 36:4 (2015), 313–320.
3. Sharma, S., Misra, C.S., Arumugam, S., Roy, S., Shah, V., Davis, J.A., Antidiabetic activity of resveratrol, a known SIRT1 activator in a genetic model for type-2 diabetes. Phytother. Res 25:1 (2011), 67–73.
4. Lekli, I., Szabo, G., Juhasz, B., Das, S., Das, M., Varga, E., Protective mechanisms of resveratrol against ischemia-reperfusion-induced damage in hearts obtained from Zucker obese rats: the role of GLUT-4 and endothelin. Am. J. Physiol. Heart. Circ. Physiol. 294 (2008), H859–H866.
5. Rangika, B.S., Dayananda, D., Peiris, L.D.C., Hypoglycemic and hypolipidemic activities of aqueous extract of flowers from Nyctanthes arbor-tristis L. in mice BMC. Complement. Altern Med., 15(289), 2015, 10.1186/s12906-015-0807-0.
6. Su, H.C., Hung, L.M., Chen, J.K., Resveratrol, a red wine antioxidant, possesses an insulin-like effect in streptozotocin-induced diabetic rats. Am. J. Physiol. Endocrinol. Metab. 290:6 (2006), E1339–E1346.
7. Palsamy, P., Subramanian, S., Modulatory effects of resveratrol on attenuating the key enzymes activities of carbohydrate metabolism in streptozotocin–nicotinamide-induced diabetic rats. Chem. Biol. Interact. 179:2 (2009), 356–362.
8. Szkudelski, T., Resveratrol inhibits insulin secretion from rat pancreatic islets. Eur. J. Pharmacol. 552:1 (2006), 176–181.
9. Knop, F.K., Konings, E., Timmers, S., Schrauwen, P., Holst, J.J., Blaak, E.E., Thirty days of resveratrol supplementation does not affect postprandial incretin hormone responses, but suppresses postprandial glucagon in obese subjects. Diabet. Med. 30:10 (2013), 1214–1218.
10. Szkudelski, T., Szkudelska, K., Anti-diabetic effects of resveratrol. Ann. N. Y. Acad. Sci. 1215:1 (2011), 34–39.
11. Accessed 12 February 2017, Available: http://www.chemspider.com/Chemical-Structure.392875.html.
12. Daneman, D., Type 1 diabetes. Lancet 367:9513 (2006), 847–858.
13. Chang, C.C., Chang, C.Y., Huang, J.P., Hung, L.M., Effect of resveratrol on oxidative and inflammatory stress in liver and spleen of streptozotocin-induced type 1 diabetic rats. Chin. J. Physiol. 55:3 (2012), 192–201.
14. Oyenihi, O.R., Oyenihi, A.B., Adeyanju, A.A., Oguntibeju, O.O., Antidiabetic effects of resveratrol: the way forward in its clinical utility. J. Diabetes Res. 2016 (2016), 1–14.
15. Szkudelski, T., Szkudelska, K., Resveratrol and diabetes: from animal to human studies. Mol. Basis Dis. 1852:6 (2015), 1145–1154.
16. Xu, F., Wang, Y., Cui, W., Yuan, H., Sun, J., Wu, M., et al. Resveratrol prevention of diabetic nephropathy is associated with the suppression of renal inflammation and mesangial cell proliferation: possible roles of Akt/NF-??B pathway. Int. J. Endocrinol., 2014, 2014, 289327.
17. Wu, L., Zhang, Y., Ma, X., Zhang, N., Qin, G., The effect of resveratrol on FoxO1 expression in kidneys of diabetic nephropathy rats. Mol. Biol. Rep. 39:9 (2012), 9085–9093.
18. Elbe, H., Vardi, N., Esrefoglu, M., Ates, B., Yologlu, S., Taskapan, C., Amelioration of streptozotocin-induced diabetic nephropathy by melatonin, quercetin, and resveratrol in rats. Hum. Exp. Toxicol. 34:1 (2015), 100–113.
19. Bastianetto, S., Ḿenard, C., Quirion, R., Neuroprotective action of resveratrol. Biochim. Biophys. Acta. Mol. Basis. Dis. 1852:6 (2015), 1195–1201.
20. Kumar, A., Kaundal, R.K., Iyer, S., Sharma, S.S., Effects of resveratrol on nerve functions, oxidative stress and DNA fragmentation in experimental diabetic neuropathy. Life Sci. J. 80:13 (2007), 1236–1244.
21. Kumar, A., Negi, G., Sharma, S.S., Neuroprotection by resveratrol in diabetic neuropathy: concepts & mechanisms. Curr. Med. Chem. 20:36 (2013), 4640–4645.
22. Kubota, S., Ozawa, Y., Kurihara, T., Sasaki, M., Yuki, K., Miyake, S., et al. Roles of AMP-activated protein kinase in diabetes-induced retinal inflammation. Invest. Ophthalmol. Vis. Sci. 52:12 (2012), 9142–9148.
23. Hua, J., Guerin, K.I., Chen, J., Michan, S., Stahl, A., Krah, N.M., et al. Resveratrol inhibits pathologic retinal neovascularization in Vldlr-/- mice. Invest. Ophthalmol. Vis. Sci. 52:5 (2011), 2809–2816.
24. Kim, Y.H., Kim, Y.S., Roh, G.S., Choi, W.S., Cho, G.J., Resveratrol blocks diabetes-induced early vascular lesions and vascular endothelial growth factor induction in mouse retinas. Acta Ophthalmol. 90:1 (2012), e31–e37.
25. Soufi, F.G., Mohammad-nejad, D., Ahmadieh, H., Resveratrol improves diabetic retinopathy possibly through oxidative stress—nuclear factor??B—apoptosis pathway. Pharmacol. Rep. 64:6 (2012), 1505–1514.
26. Allah, O.M.A., El-Debakey, F., Prophylactic resveratrol and telmisartan combination ameliorates experimentally induced diabetic nephropathy in rats, focus on the pro-sclerotic cytokine, transforming growth factor-??1 (TGF-??1). Med. J. Cairo Univ., 78(2), 2010.
27. Vella, R.K., Pullen, C., Coulson, F.R., Fenning, A.S., Resveratrol prevents cardiovascular complications in the SHR/STZ rat by reductions in oxidative stress and inflammation. Biomed. Res Int., 2015, 2015, 918123.
28. Guo, R., Liu, B., Wang, K., Zhou, S., Li, W., Xu, Y., Resveratrol ameliorates diabetic vascular inflammation and macrophage infiltration in db/db mice by inhibiting the NF-??B pathway. Diab. Vasc. Dis. Res. 11:2 (2014), 92–102.
29. Turan, B., Tuncay, E., Vassort, G., Resveratrol and diabetic cardiac function: focus on recent in vitro and in vivo studies. J. Bioenergy Biomembr. 44:2 (2012), 281–296.
30. Mohammadshahi, M., Haidari, F., Soufi, F.G., Chronic resveratrol administration improves diabetic cardiomyopathy in part by reducing oxidative stress. J. Cardiol. 21:1 (2014), 39–46.
31. Hamadi, N., Mansour, A., Hassan, M.H., Khalifi-Touhami, F., Badary, O., Ameliorative effects of resveratrol on liver injury in streptozotocin-induced diabetic rats. J. Biochem. Mol. Toxicol. 26:10 (2012), 384–392.
32. Hussein, M.A., El-Maksoud, H.A., Biochemical effects of Resveratrol and curcumin combination on obese diabetic rats. Mol. Clin. Pharmacol. 4:1 (2013), 1–10.
33. Arrick, D.M., Sun, H., Patel, K.P., Mayhan, W.G., Chronic resveratrol treatment restores vascular responsiveness of cerebral arterioles in type 1 diabetic rats. Am. J. Physiol. Lung Cell. Mol. Physiol. 301:3 (2011), H696–H703.
34. Yar, A.S., Menevse, S., Alp, E., The effects of resveratrol on cyclooxygenase-1 and −2, nuclear factor kappa beta, matrixmetalloproteinase-9, and sirtuin 1 mRNA expression in hearts of streptozotocin-induced diabetic rats. Genet. Mol. Res. 10:4 (2011), 2962–2975.
35. Lagouge, M., Argmann, C., Gerhart-Hines, Z., Meziane, H., Lerin, C., Daussin, F., et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1??. Cell 127:6 (2006), 1109–1122.
36. Chaudhary, N., Pfluger, P.T., Metabolic benefits from sirt1and sirt1 activators. Curr. Opin. Clin. Nutr. Metab. Care 12:4 (2009), 431–437.
37. Milne, J.C., Lambert, P.D., Schenk, S., Carney, D.P., Smith, J.S., Gagne, D.J., et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 450:7170 (2007), 712–716.
38. De Kreutzenberg, S.V., Ceolotto, G., Papparella, I., Bortoluzzi, A., Semplicini, A., Man, C.D., et al. Downregulation of the longevity-associated protein sirtuin1 in insulin resistance and metabolic syndrome: potential biochemical mechanisms. Diabetes 59:4 (2010), 1006–1015.
39. Palsamy, P., Subramanian, S., Resveratrol protects diabetic kidney by attenuating hyperglycemia-mediated oxidative stress and renal inflammatory cytokines via Nrf2-Keap1 signaling. Biochim. Biophys. Acta Mol. Basis Dis. 1812:7 (2011), 719–731.
40. Chang, C.C., Chang, C.Y., Huang, J.P., Hung, L.M., Effect of resveratrol on oxidative and inflammatory stress in liver and spleen of streptozotocin-induced type 1 diabetic rats. Chin. J. Physiol. 55:3 (2012), 192–201.
41. Schmatz, R., Perreira, L.B., Stefanello, N., Mazzanti, C., Spanevello, R., Gutierres, J., et al. Effects of resveratrol on biomarkers of oxidative stress and on the activity of delta aminolevulinic acid dehydratase in liver and kidney of streptozotocin-induced diabetic rats. Biochimie 94:2 (2012), 374–383.
42. Carolo dos Santos, K., Pereira Braga, C., Octavio Barbanera, P., Seiva, F.R.F., Fernandes, A. Jr., Fernandes, A.A.H., Cardiac energy metabolism and oxidative stress biomarkers in diabetic rat treated with resveratrol. PLoS One, 9(7), 2014, e102775.
43. Kumar, A., Sharma, S.S., NF-??B inhibitory action of resveratrol: a probable mechanism of neuroprotection in experimental diabetic neuropathy. Biochem. Biophys. Res. Commun. 394:2 (2010), 360–365.
44. Ungvari, Z., Bagi, Z., Feher, A., Recchia, F.A., Sonntag, W.E., Pearson, K., et al. Resveratrol confers endothelial protection via activation of the antioxidant transcription factor Nrf2. Am. J. Physiol. Heart Circ. Physiol. 299:1 (2010), H18–H24.
45. Hao, J., Chen, C., Huang, K., Huang, J., Li, J., Liu, P., et al. Polydatin improves glucose and lipid metabolism in experimental diabetes through activating the Akt signaling pathway. Eur. J. Pharmacol. 745 (2014), 152–165.
46. Wang, Y., Ye, J., Li, J., Chen, C., Huang, J., Liu, P., et al. Polydatin ameliorates lipid and glucose metabolism in type 2 diabetes mellitus by downregulating proprotein convertase subtilisin/kexin type 9 (PCSK9). Cardiovasc. Diabetol., 15(1), 2016, 19.
47. Chen, C., Huang, K., Hao, J., Huang, J., Yang, Z., Xiong, F., et al. Polydatin attenuates AGEs-induced upregulation of fibronectin and ICAM-1 in rat glomerular mesangial cells and db/db diabetic mice kidneys by inhibiting the activation of the SphK1-S1P signaling pathway. Mol. Cell. Endocrinol. 427 (2016), 45–56.
48. Smoliga, J.M., Blanchard, O., Enhancing the delivery of resveratrol in humans: if low bioavailability is the problem, what is the solution?. Molecules 19:11 (2014), 17154–17172.
49. Kuršvietienė, L., Stanevičienė, I., Mongirdienė, A., Bernatonienė, J., Multiplicity of effects and health benefits of resveratrol. Medicina (Mex) 52:3 (2016), 148–155.
50. Coimbra, M., Isacchi, B., van Bloois, L., Torano, J.S., Ket, A., et al. Improving solubility and chemical stability of natural compounds for medicinal use by incorporation into liposomes. Int. J. Pharm. 416:2 (2011), 433–442.
51. Zhang, J.Q., Jiang, K.M., Xie, X.G., Jin, Y., Lin, J., Water-soluble inclusion complexes of trans-polydatin by cyclodextrin complexation: preparation, characterization and bioactivity evaluation. J. Mol. Liq. 219 (2016), 592–598.
52. Gupta, P., Bala, M., Gupta, S., Dua, A., Dabur, R., Injeti, E., et al. Efficacy and risk profile of anti-diabetic therapies: conventional vs traditional drugs – a mechanistic revisit to understand their mode of action. Pharmacol. Res. 113 (2016), 636–674.
53. Goh, K.P., Lee, H.Y., Lau, D.P., Supaat, W., Chan, Y.H., Koh, A.F.Y., Effects of resveratrol in patients with type 2 diabetes mellitus on skeletal muscle SIRT1 expression and energy expenditure. Int. J. Sport Nutr. Exerc. Metab. 24:1 (2014), 2–13.
54. Brasnyó, P., Molnár, G.A., Mohás, M., Markó, L., Laczy, B., Cseh, J., Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. Br. J. Nutr. 106:03 (2011), 383–389.
55. Méndez-del Villar, M., González-Ortiz, M., Martínez-Abundis, E., Pérez-Rubio, K.G., Lizárraga-Valdez, R., Effect of resveratrol administration on metabolic syndrome, insulin sensitivity and insulin secretion. Metab. Syndr. Relat. Disord. 12:10 (2014), 497–501.
56. Most, J., Goossens, G.H., Jocken, J.W.E., Blaak, E.E., Short-term supplementation with a specific combination of dietary polyphenols increases energy expenditure and alters substrate metabolism in overweight subjects. Int. J. Obes. 38:5 (2014), 698–706.
57. Bashmakov, Y.K., Assaad-Khalil, S.H., Abou Seif, M., Udumyan, R., Megallaa, M., Rohoma, K.H., Resveratrol promotes foot ulcer size reduction in type 2 diabetes patients. ISRN Endocrinol., 2014, 1–8.
58. Movahed, A., Nabipour, I., Lieben, L.X., Thandapilly, S.J., Kalantarhormozi, Yu L.M., Antihyperglycemic effects of short term resveratrol supplementation in type 2 diabetic patients. Evid. Based Complement. Alternat. Med., 2013, 1–11.
59. Thazhath, S.S., Wu, T., Bound, M.J., Checklin, H.L., Standfield, S., Jones, K., Administration of resveratrol for 5 wk has no effect on glucagon-like peptide 1 secretion, gastric emptying, or glycemic control in type 2 diabetes: a randomized controlled trial. Am. J. Clin. Nutr. 103:1 (2016), 66–70.
60. Bo, S., Ponzo, V., Ciccone, G., Evangelista, A., Saba, F., Goitre, I., Six months of resveratrol supplementation has no measurable effect in type 2 diabetic patients. A randomized, double blind, placebo-controlled trial. Pharmacol. Res. 111 (2016), 896–905.
61. Snead, W., Resveratrol-Leucine Metabolite Synergy in Pre-diabetes. 2012 (Accessed 15 February 2017. Available: https://clinicaltrials.gov/ct2/show/NCT01593605?term=resveratrol+diabetes+mellitus&rank=6).
62. Goh, K.P., Effects of High-Dose Resveratrol in Non-Diabetic Obese Males. 2009 (Accessed 15 February 2017. Available: https://clinicaltrials.gov/ct2/show/record/NCT02247596?term=resveratrol+diabetes+mellitus&rank=13).
63. Dash, S., Regulation of Intestinal and Hepatic Lipoprotein Secretion by Resveratrol. 2011 (Accessed 15 February 2017. Available: https://clinicaltrials.gov/ct2/show/record/NCT01451918?term=resveratrol+diabetes+mellitus&rank=21).
64. Vita, J.A., Pilot Study of the Effects of Resveratrol on Endothelial Function in Subjects with Type 2 Diabetes Mellitus. 2009 (Accessed 15 February 2017. Available: https://clinicaltrials.gov/ct2/show/study/NCT01038089?term=resveratrol+diabetes+mellitus&rank=1).
65. Klein, S., Effect of Resvida, a Comparison with Calorie Restriction Regimen (Resvida). 2009 (Accessed 15 February 2017. Available: https://clinicaltrials.gov/ct2/show/record/NCT00823381?term=resveratrol+diabetes+mellitus&rank=23).
66. Jørgensen, J.O.L., Potential Beneficial Effects of Resveratrol. 2010 (Accessed 15 February 2017. Available: https://clinicaltrials.gov/ct2/show/record/NCT01150955?term=resveratrol+diabetes+mellitus&rank=26).